LT2961742T - Amidų junginiai, skirti živ gydymui - Google Patents

Amidų junginiai, skirti živ gydymui

Info

Publication number
LT2961742T
LT2961742T LTEP14712844.1T LT14712844T LT2961742T LT 2961742 T LT2961742 T LT 2961742T LT 14712844 T LT14712844 T LT 14712844T LT 2961742 T LT2961742 T LT 2961742T
Authority
LT
Lithuania
Prior art keywords
hiv
treatment
amide compounds
amide
compounds
Prior art date
Application number
LTEP14712844.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Gediminas BRIZGYS
Eda Canales
Chien-Hung Chou
Michael Graupe
Yunfeng Hu
John Link
Qi Liu
Yafan Lu
Roland Saito
Scott Schroeder
John Somoza
Winston Tse
Jennifer Zhang
Randall HALCOMB
Scott E. Lazerwith
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2961742(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of LT2961742T publication Critical patent/LT2961742T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP14712844.1T 2013-03-01 2014-02-28 Amidų junginiai, skirti živ gydymui LT2961742T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771655P 2013-03-01 2013-03-01
US201361857636P 2013-07-23 2013-07-23
PCT/US2014/019663 WO2014134566A2 (en) 2013-03-01 2014-02-28 Therapeutic compounds

Publications (1)

Publication Number Publication Date
LT2961742T true LT2961742T (lt) 2018-09-25

Family

ID=50382584

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14712844.1T LT2961742T (lt) 2013-03-01 2014-02-28 Amidų junginiai, skirti živ gydymui

Country Status (38)

Country Link
US (4) US20140303164A1 (https=)
EP (3) EP3409667B1 (https=)
JP (6) JP6519486B2 (https=)
KR (1) KR102229989B1 (https=)
CN (2) CN108516974A (https=)
AP (1) AP2015008717A0 (https=)
AU (3) AU2014223973B2 (https=)
BR (1) BR112015021027B1 (https=)
CA (2) CA2901502C (https=)
CL (1) CL2015002445A1 (https=)
CR (2) CR20190504A (https=)
CU (1) CU24340B1 (https=)
CY (1) CY1121047T1 (https=)
DK (1) DK2961742T3 (https=)
EA (1) EA035127B1 (https=)
ES (2) ES2688571T3 (https=)
HK (1) HK1260892A1 (https=)
HR (1) HRP20181679T1 (https=)
HU (1) HUE039521T2 (https=)
IL (1) IL240519B (https=)
LT (1) LT2961742T (https=)
MD (1) MD20150092A2 (https=)
MX (1) MX375170B (https=)
MY (1) MY195364A (https=)
NZ (3) NZ728537A (https=)
PE (2) PE20191461A1 (https=)
PH (1) PH12015501881B1 (https=)
PL (2) PL2961742T3 (https=)
PT (2) PT2961742T (https=)
RS (1) RS57718B1 (https=)
SG (2) SG11201506929VA (https=)
SI (2) SI2961742T1 (https=)
SM (1) SMT201800522T1 (https=)
TW (2) TWI694071B (https=)
UA (1) UA120346C2 (https=)
UY (1) UY35362A (https=)
WO (1) WO2014134566A2 (https=)
ZA (1) ZA201506098B (https=)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
MX2015010775A (es) * 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) * 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
WO2016123629A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10221129B2 (en) 2015-04-23 2019-03-05 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2016172425A1 (en) 2015-04-23 2016-10-27 Viiv Healthcare (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20170040479A1 (en) 2015-08-07 2017-02-09 Solaero Technologies Corp. Reliable interconnection of solar cells
US20170081324A1 (en) * 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP3478661A1 (en) 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Aza-substituted inhibitors of human immunodeficiency virus replication
EP3478703A1 (en) 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
JP6936820B2 (ja) 2016-06-30 2021-09-22 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのアザデカリン誘導体
CN119462611A (zh) * 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (en) * 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
EP3774775B8 (en) 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
EP3833436A1 (en) * 2018-08-09 2021-06-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2971987T3 (es) 2018-10-24 2024-06-10 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de inmunodeficiencia humana
JP7500555B2 (ja) * 2018-10-25 2024-06-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
EP3873607B1 (en) 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20220211704A1 (en) 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
BR112021025655A2 (pt) 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
EP4038068A1 (en) 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
EP4038064B1 (en) 2019-10-01 2024-02-21 VIIV Healthcare UK (No.5) Limited N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
CA3157275C (en) 2019-11-26 2026-02-10 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
BR112022010204A2 (pt) 2019-11-29 2022-09-06 Jiangsu Hengrui Medicine Co Derivado do anel de piridina fusionado, método de preparação para o mesmo e uso farmacêutico do mesmo
JP2023513047A (ja) * 2020-01-30 2023-03-30 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に有効な縮合二環式芳香族複素環式アミノ化合物
EP4114527A1 (en) 2020-03-06 2023-01-11 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022020933A2 (pt) 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
TWI858267B (zh) * 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
PL4244396T3 (pl) 2020-11-11 2025-12-22 Gilead Sciences, Inc. Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120
CN118159529A (zh) * 2021-05-28 2024-06-07 江苏恒瑞医药股份有限公司 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法
US12404262B2 (en) 2021-12-03 2025-09-02 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
CR20240223A (es) 2021-12-03 2024-07-08 Gilead Sciences Inc Compuestos terapéuticos para la infección por el virus del vih
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TWI867601B (zh) * 2022-07-01 2024-12-21 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
CN121219281A (zh) 2023-05-31 2025-12-26 吉利德科学公司 用于治疗hiv的化合物的固体形式
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250367381A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240387A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367382A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367386A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367385A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
CN118666903A (zh) * 2024-06-17 2024-09-20 石家庄迪斯凯威医药科技有限公司 一种具有抗病毒活性的化合物
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010493B1 (en) 2006-04-12 2016-01-27 Merck Sharp & Dohme Corp. Pyridyl amide t-type calcium channel antagonists
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
AU2008317353B2 (en) * 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
CN102414217A (zh) 2009-02-25 2012-04-11 彼格泰格私人有限公司 用于检测基孔肯雅病毒的探针和引物
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110035387A1 (en) * 2009-08-10 2011-02-10 Telcordia Technologies, Inc. System and method for the controlled introduction of noise to information filtering
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
SI2688403T1 (sl) 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US20140155381A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
WO2014028931A2 (en) 2012-08-17 2014-02-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
AU2014340110B2 (en) 2013-10-24 2018-07-12 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2016172425A1 (en) 2015-04-23 2016-10-27 Viiv Healthcare (No.5) Limited Inhibitors of human immunodeficiency virus replication
US10221129B2 (en) 2015-04-23 2019-03-05 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP6620763B2 (ja) * 2017-01-16 2019-12-18 マツダ株式会社 電動車両

Also Published As

Publication number Publication date
US20210009555A1 (en) 2021-01-14
EP2961742B1 (en) 2018-08-01
SMT201800522T1 (it) 2018-11-09
PH12015501881A1 (en) 2016-01-11
PE20191461A1 (es) 2019-10-16
HRP20181679T1 (hr) 2018-12-14
AP2015008717A0 (en) 2015-09-30
ES2688571T3 (es) 2018-11-05
JP2023101723A (ja) 2023-07-21
EP3954679A2 (en) 2022-02-16
JP2018141018A (ja) 2018-09-13
RS57718B1 (sr) 2018-12-31
DK2961742T3 (en) 2018-09-24
CU24340B1 (es) 2018-05-08
EA035127B1 (ru) 2020-04-30
KR102229989B1 (ko) 2021-03-18
EP3409667B1 (en) 2021-07-21
CA2901502C (en) 2018-07-17
SG10201710764YA (en) 2018-02-27
HUE039521T2 (hu) 2019-01-28
AU2014223973A1 (en) 2015-09-10
WO2014134566A3 (en) 2014-12-24
MX375170B (es) 2025-03-06
PH12015501881B1 (en) 2016-01-11
AU2016262671B2 (en) 2018-11-08
CN105705500A (zh) 2016-06-22
HK1226078B (zh) 2017-09-22
AU2018247348A1 (en) 2018-11-08
NZ728537A (en) 2018-08-31
EP2961742A2 (en) 2016-01-06
KR20150121720A (ko) 2015-10-29
AU2014223973B2 (en) 2016-12-22
EP3409667A1 (en) 2018-12-05
JP6893899B2 (ja) 2021-06-23
SG11201506929VA (en) 2015-10-29
BR112015021027A2 (pt) 2017-07-18
US9951043B2 (en) 2018-04-24
CN108516974A (zh) 2018-09-11
UY35362A (es) 2014-08-29
CY1121047T1 (el) 2019-12-11
PE20151749A1 (es) 2015-12-12
CN105705500B (zh) 2018-05-29
NZ742681A (en) 2019-05-31
JP2019214599A (ja) 2019-12-19
PL2961742T3 (pl) 2018-12-31
AU2016262671A1 (en) 2016-12-08
CR20190504A (es) 2020-03-11
IL240519A0 (en) 2015-10-29
UA120346C2 (uk) 2019-11-25
JP2025085700A (ja) 2025-06-05
JP2022009742A (ja) 2022-01-14
CU20150096A7 (es) 2016-07-29
EA201591457A8 (ru) 2018-05-31
TWI706945B (zh) 2020-10-11
JP6519486B2 (ja) 2019-05-29
PL3409667T3 (pl) 2021-12-13
US20180273508A1 (en) 2018-09-27
EP3954679A3 (en) 2022-04-20
US20140303164A1 (en) 2014-10-09
TW201938551A (zh) 2019-10-01
HK1222169A1 (en) 2017-06-23
ES2887578T3 (es) 2021-12-23
CA3007006A1 (en) 2014-09-04
PT2961742T (pt) 2018-10-26
BR112015021027B1 (pt) 2020-02-18
PT3409667T (pt) 2021-09-16
BR112015021027A8 (pt) 2020-01-14
CR20150454A (es) 2015-11-20
IL240519B (en) 2020-11-30
US20160108030A1 (en) 2016-04-21
WO2014134566A2 (en) 2014-09-04
CL2015002445A1 (es) 2016-02-19
SI3409667T1 (sl) 2021-11-30
SI2961742T1 (sl) 2018-11-30
EA201591457A1 (ru) 2016-03-31
TWI694071B (zh) 2020-05-21
MD20150092A2 (ro) 2016-02-29
HK1260892A1 (zh) 2019-12-27
MX2015011478A (es) 2016-02-03
ZA201506098B (en) 2022-05-25
TW201446755A (zh) 2014-12-16
CA2901502A1 (en) 2014-09-04
MY195364A (en) 2023-01-16
JP2016510038A (ja) 2016-04-04
NZ631754A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
ZA201506098B (en) Amide compounds for the treatment of hiv
IL245408B (en) Converted benzamides for the treatment of arthropods
IL253052A0 (en) Isoquinoline compounds for the treatment of hiv
IL243976B (en) kdm1a inhibitors for disease treatment
SMT201700498T1 (it) Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv
SMT201700525T1 (it) Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv
IL281072B (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EP2948129A4 (en) THERAPEUTIC COMPOUNDS
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
GB201311169D0 (en) Therapeutic compounds